PMC:7274950 / 2504-2765 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T32","span":{"begin":32,"end":36},"obj":"CHEBI:33290;CHEBI:33290"},{"id":"T33","span":{"begin":41,"end":45},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T34","span":{"begin":251,"end":257},"obj":"UBERON:0007023"},{"id":"T86774","span":{"begin":32,"end":36},"obj":"CHEBI:33290;CHEBI:33290"},{"id":"T28077","span":{"begin":41,"end":45},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T21527","span":{"begin":251,"end":257},"obj":"UBERON:0007023"}],"text":"the only ERT approved by the US Food and Drug Administration since 2003 [6]. Migalastat (Galafold®) was approved in Europe in May 2016, in Canada in September 2017, in Japan in March 2017 and in the USA in August 2018 for long-term treatment of FD in adults wit"}

{"project":"LitCovid-PubTator","denotations":[{"id":"86","span":{"begin":77,"end":87},"obj":"Chemical"},{"id":"87","span":{"begin":89,"end":97},"obj":"Chemical"},{"id":"89","span":{"begin":245,"end":247},"obj":"Disease"}],"attributes":[{"id":"A86","pred":"tao:has_database_id","subj":"86","obj":"MESH:C090092"},{"id":"A87","pred":"tao:has_database_id","subj":"87","obj":"MESH:C090092"},{"id":"A89","pred":"tao:has_database_id","subj":"89","obj":"MESH:D004402"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"the only ERT approved by the US Food and Drug Administration since 2003 [6]. Migalastat (Galafold®) was approved in Europe in May 2016, in Canada in September 2017, in Japan in March 2017 and in the USA in August 2018 for long-term treatment of FD in adults wit"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T25","span":{"begin":245,"end":247},"obj":"Disease"}],"attributes":[{"id":"A25","pred":"mondo_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MONDO_0010526"}],"text":"the only ERT approved by the US Food and Drug Administration since 2003 [6]. Migalastat (Galafold®) was approved in Europe in May 2016, in Canada in September 2017, in Japan in March 2017 and in the USA in August 2018 for long-term treatment of FD in adults wit"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T25","span":{"begin":213,"end":217},"obj":"http://purl.obolibrary.org/obo/CLO_0001185"}],"text":"the only ERT approved by the US Food and Drug Administration since 2003 [6]. Migalastat (Galafold®) was approved in Europe in May 2016, in Canada in September 2017, in Japan in March 2017 and in the USA in August 2018 for long-term treatment of FD in adults wit"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T11","span":{"begin":245,"end":247},"obj":"Chemical"}],"attributes":[{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_73631"}],"text":"the only ERT approved by the US Food and Drug Administration since 2003 [6]. Migalastat (Galafold®) was approved in Europe in May 2016, in Canada in September 2017, in Japan in March 2017 and in the USA in August 2018 for long-term treatment of FD in adults wit"}